Bisphosphonates May Not Protect Against Breast Cancer
the Cancer Therapy Advisor take:
Bisphosphonates, such as alendronate, risedronate, ibandronate, pamidronate, and zoledronic acid, used to treat osteoporosis in postmenopausal women have been thought to reduce the risk of developing breast cancer; however, according to new research published in The Journal of the American Medical Association, that belief may not be true. Researchers at the University of California, San Francisco assessed whether alendronate or zoledronic acid would reduce the risk of breast cancer in two large clinical trials and they found that neither drug conferred protection.
In the alendronate study, 1.8% of women taking the drug developed breast cancer while 1.5% of those taking placebo developed the disease during an average follow-up period of nearly 4 years. In the zoledronic acid trial, 0.87% of those taking the drug and 0.77% of those taking placebo developed breast cancer during an average follow-up of about 3 years.
The researchers suggest that low estrogen, not bisphosphonates, lowered the incidence of breast cancer in postmenopausal women with osteoporosis in previous observational studies. Because those women naturally had low estrogen due to being postmenopausal, they already had a lower risk of developing breast cancer than women with normal estrogen levels. Researchers recommend that women with osteoporosis continue to take bisphosphonates to prevent fractures, but that they be aware that these drugs will not reduce their risk of developing breast cancer.
Bisphosphonates may not protect women from breast cancer as had been thought.
Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco (UCSF).
The drugs' protective effect was widely assumed after several observational studies showed that women who took them were less likely to get breast cancer.
But when researchers assessed the effect of two of the most widely used osteoporosis drugs – sold under the brand names, Fosamax and Reclast – in two large randomized clinical trials, neither drug protected women with osteoporosis from getting breast cancer. The results were published August 11, 2014, in JAMA Internal Medicine.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer